Nesyrgy (Amlodipine Besilate, Nebivolol Hydrochloride)

Amlodipine besilate / nebivolol hydrochloride, the active ingredient in Nesyrgy, is a calcium channel blocker and beta‑blocker combination presented as an oral tablet for oral use. It is employed to lower elevated blood pressure in adult patients with hypertension.

GNH USA supplies Nesyrgy as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product meets EU quality standards and is distributed under strict regulatory compliance.

Nesyrgy, a combined calcium‑channel blocker and beta‑blocker, is indicated for the management of hypertension.

Hypertension: reduces systolic and diastolic blood pressure, helping prevent cardiovascular complications. Essential hypertension: provides consistent blood pressure control in patients not adequately managed by monotherapy. Elevated blood pressure: improves overall vascular resistance and supports long‑term cardiovascular health.

Common Side Effects: - Headache - Peripheral edema - Dizziness or light‑headedness - Flushing - Fatigue - Palpitations

Serious or Rare Side Effects: - Severe hypotension - Bradycardia or heart block - Angioedema - Hepatic dysfunction - Bronchospasm in susceptible patients

Before initiating therapy, consider the following precautions: - Monitor blood pressure regularly: ensure therapeutic targets are reached without excessive drop. - Assess cardiac function: avoid use in patients with severe heart failure or recent myocardial infarction. - Use caution in hepatic impairment: dose adjustments may be required. - Avoid abrupt discontinuation: taper gradually to prevent rebound hypertension. - Evaluate for contraindications such as cardiogenic shock or severe aortic stenosis. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Nesyrgy may interact with several medicines; review patient medication lists carefully. Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase amlodipine levels. - Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may raise nebivolol concentrations. - Non‑dihydropyridine calcium channel blockers (e.g., verapamil, diltiazem): additive negative inotropic effects. Moderate Interactions (Monitor Closely):\n- Diuretics: may enhance antihypertensive effect, requiring blood pressure monitoring. - NSAIDs: can blunt antihypertensive response, necessitating dose adjustments. - Alcohol: may increase risk of hypotension and dizziness.